The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction

Gibson, C. Michael ; Kerneis, Mathieu ; Yee, Megan K. ; Daaboul, Yazan ; Korjian, Serge ; Mehr, Ali Poyan ; Tricoci, Pierluigi ; Alexander, John H. ; Kastelein, John J.P. ; Mehran, Roxana ; Bode, Christoph ; Lewis, Basil S. ; Mehta, Ravindra ; Duffy, Danielle ; Feaster, John ; Halabi, Majdi ; Angiolillo, Dominick J. ; Duerschmied, Daniel ; Ophuis, Ton Oude ; Merkely, Bela

The American heart journal, 2019-02, Vol.208, p.81-90 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível